Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Long-Term Debt Repayments (2019 - 2021)

Fulcrum Therapeutics (FULC) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $1000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Long-Term Debt Repayments fell 92.31% to $1000.0 in Q4 2021 year-over-year; TTM through Sep 2022 was $1000.0, a 96.67% decrease, with the full-year FY2021 number at $18000.0, down 64.0% from a year prior.
  • Long-Term Debt Repayments was $1000.0 for Q4 2021 at Fulcrum Therapeutics, up from -$1000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $13000.0 in Q3 2019 to a low of -$1000.0 in Q3 2021.
  • A 3-year average of $9416.7 and a median of $11500.0 in 2019 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: grew 20.0% in 2020, then crashed 107.69% in 2021.
  • Fulcrum Therapeutics' Long-Term Debt Repayments stood at $11000.0 in 2019, then grew by 18.18% to $13000.0 in 2020, then plummeted by 92.31% to $1000.0 in 2021.
  • Per Business Quant, the three most recent readings for FULC's Long-Term Debt Repayments are $1000.0 (Q4 2021), -$1000.0 (Q3 2021), and $5000.0 (Q2 2021).